Antigen‐Targeting Inserted Nanomicelles Guide Pre‐Existing Immunity to Kill Head and Neck Cancer
A significant challenge in cancer therapy is the identification of suitable targets that are specifically and uniformly expressed across heterogeneous tumors. The efficacy of pre-existing antiviral immunity in tumor treatment is limited by the absence of corresponding targets. This study develops a novel platform of antigen-targeted inserted nanomicelles, preS1 (an antigen of hepatitis B virus)-pHLIP nanomicelles, in which tumor-targeting nanomicelles release antigens that label tumor tissue for pre-existing immunity-mediated lysis in situ. In animal models of head and neck cancers, including head and neck squamous cell carcinoma and anaplastic thyroid cancer, preS1-pHLIP nanomicelles effectively inhibited tumor growth, recurrence, and metastasis in animals pre-immunized with preS1. This therapeutic effect is associated with an increase in the proportion of preS1-specific B cells and activated tumor-specific T cells within the tumor microenvironment. Overall, this work has engineered a nanomicelle that can disguise tumor cells as viruses and achieve tumor killing through the pre-existing antiviral immune response. This strategy presents a novel approach for treating tumors with ambiguous therapeutic target profiles.
Authors
- Xiao Zhao (ORCID: https://orcid.org/0000-0002-4504-5670)
- Gaofeng Hu
- Liehao Jiang
- Jiajie Xu (ORCID: https://orcid.org/0000-0001-5539-3831)
- Y L Li
- Tiefeng Jin (ORCID: https://orcid.org/0000-0001-8957-696X)
- Lizhuo Zhang (ORCID: https://orcid.org/0000-0002-4460-1743)
- Keman Cheng (ORCID: https://orcid.org/0009-0006-6646-0095)
- Zhangguo Ying
- Xinyang Ge (ORCID: https://orcid.org/0000-0001-6030-2068)
- Chuanming Zheng
- Dan Wang (ORCID: https://orcid.org/0000-0001-9239-7399)
- Qinglin Li (ORCID: https://orcid.org/0000-0001-8469-0923)
- Qingqing Feng (ORCID: https://orcid.org/0000-0002-0230-5049)
- Jiafeng Wang (ORCID: https://orcid.org/0000-0002-2360-5032)
- Minghua Ge (ORCID: https://orcid.org/0000-0002-3178-1466)
- Zhuo Tan
Institutions
- IE University (ES)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- University of Macau (MO)
- Peking Union Medical College Hospital (CN)
- Zhejiang Cancer Hospital (CN)
- Zhejiang Provincial People's Hospital (CN)
- Zhejiang Center for Disease Control and Prevention (CN)
- National Center for Nanoscience and Technology (CN)
- Hangzhou Medical College (CN)
Publication Details
- Journal
- Advanced Science
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1002/advs.202410629
- Citations
- 2
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
- National Key Research and Development Program of China
- Natural Science Foundation of Zhejiang Province